<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57150">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362074</url>
  </required_header>
  <id_info>
    <org_study_id>P14-455</org_study_id>
    <nct_id>NCT02362074</nct_id>
  </id_info>
  <brief_title>Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>P @ Work</acronym>
  <official_title>Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the impact of treatment with adalimumab on work
      related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated
      in Canada.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Rheumatoid Arthritis (RA) - Work Instability</measure>
    <time_frame>From month 0 to month 24</time_frame>
    <description>This is patient-reported assessment on the impact of adalimumab on the work status of RA patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Financial Loss</measure>
    <time_frame>From month 0 to month 24</time_frame>
    <description>This is patient reported assessment of financial burden of RA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Swollen Joint Count (SJC)</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>This is assessed by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tender Joint Count (TJC)</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>This is assessed by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score (DAS) 28</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>Disease activity assessment is done by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient pain</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>Pain is assessed using Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient assessment of Global Disease Activity</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>It is assessed using VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physician's assessment of Global Disease Activity</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>It is assessed using VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>This is patient reported functional assessment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">760</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Adalimumab subjects</arm_group_label>
    <description>Subjects starting Adalimumab treatment at time of enrollment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This is a Multi-Center Canadian Observational Study that will enroll rheumatoid arthristis
        (RA) subjects for whom the treating physician has decided to treat with adalimumab.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with moderate to severe RA for whom the physician has decided to initiate
             treatment with adalimumab

          2. Adult male or female â‰¥ 18 years old that has been newly prescribed adalimumab therapy
             according to the local product label and are with PROGRESS

          3. Subjects should be evaluated for tuberculosis (TB) exposure/risk factors for active
             and latent TB

          4. Subject is able to give written patient authorization and is willing to comply with
             the requirements of this study protocol.

        Exclusion Criteria:

          1. Subject cannot or will not sign a patient authorization

          2. Subject with a known hypersensitivity to Adalimumab, or any of its components

          3. Presence of any condition that, in the opinion of the treating physician, prohibits
             the subject from participating in the study or obscures the assessment of the
             treatment of RA

          4. Subjects currently participating in an investigational clinical trial

          5. Subjects treated with &gt;1 prior biologic disease-modifying antirheumatic drugs
             (DMARDs) for RA. Any prior treatment with adalimumab is prohibited

          6. Subjects previously treated with targeted synthetic disease modifying agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Pelizon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbvie Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Desjardins</last_name>
    <phone>1-888 703 3006 ext 7305</phone>
    <email>sophie.desjardins@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique Julien, MS</last_name>
    <phone>1-888 703 3006 ext 7453</phone>
    <email>dominique.julien@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>D. A. Haaland Medicine Professional Corporation /ID# 134190</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Drs Nalin and Vandana Ahluwalia Medicine Professional Corp /ID# 136485</name>
      <address>
        <city>Brampton</city>
        <zip>L6T 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Arthritis and Osteoporosis Centre /ID# 136486</name>
      <address>
        <city>Burlington</city>
        <zip>L7L 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aviva Clinical Trial Group Inc. /ID# 134192</name>
      <address>
        <city>Burlington</city>
        <zip>L7R 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dr. Angela How, Burnaby, CA /ID# 136487</name>
      <address>
        <city>Burnaby</city>
        <zip>V5H 3P2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dr. Karen Pont, Cranbrook, BC, CA /ID# 134511</name>
      <address>
        <city>Cranbrook</city>
        <zip>V1C 2R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Chrisotomor Kouroukis &amp; Dr. Pauline Boulos MPC /ID# 151189</name>
      <address>
        <city>Dundas</city>
        <zip>L9H 1B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adachi Medicine Prof. Corp /ID# 152538</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charlton Medical Centre /ID# 138332</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Mountain Medical Center /ID# 134832</name>
      <address>
        <city>Hamilton</city>
        <zip>L9C 5N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brandusa Florica Medicine Professional Corporation /ID# 134829</name>
      <address>
        <city>Mississauga</city>
        <zip>L5A 3V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Angela Montgomery, Mississauga, Canada /ID# 136943</name>
      <address>
        <city>Mississauga</city>
        <zip>L5A 3V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Martin M.S. Lee Medicine Professional Corporation /ID# 138333</name>
      <address>
        <city>Mississauga</city>
        <zip>L5C 4P6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Credit Valley Rheumatology /ID# 134834</name>
      <address>
        <city>Mississauga</city>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Maisonneuve-Rosemont /ID# 136488</name>
      <address>
        <city>Montreal</city>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Rhumatologie de Montreal /ID# 135289</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Jan I Schulz, Montreal, CA /ID# 134193</name>
      <address>
        <city>Montreal</city>
        <zip>H3T 1Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Center of Montreal /ID# 135372</name>
      <address>
        <city>Montreal</city>
        <zip>H3Z 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique de Rhumatologie de Montreal /ID# 162186</name>
      <address>
        <city>Montreal</city>
        <zip>H4N 1C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Maqbool R. Sheriff Inc. /ID# 134831</name>
      <address>
        <city>Nanaimo</city>
        <zip>V9S 4S1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rajwinder S. Dhillon Medicine Professional Corporation /ID# 147756</name>
      <address>
        <city>Niagara Falls</city>
        <zip>L2E 6A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Capital North Therapeutics Research Inc. /ID# 134835</name>
      <address>
        <city>Ottawa</city>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Suneil Kapur, Ottawa, Canada /ID# 152537</name>
      <address>
        <city>Ottawa</city>
        <zip>K2H 9A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Yatish N. Setty, Owen Sound, ON, CA /ID# 134189</name>
      <address>
        <city>Owen Sound</city>
        <zip>N4K 4K7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Drs. M &amp; W Teo Inc. /ID# 148641</name>
      <address>
        <city>Penticton</city>
        <zip>V2A 4Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Medical Centre /ID# 134833</name>
      <address>
        <city>Peterborough</city>
        <zip>K9J 2V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de recherche du CHUQ - CRCEO /ID# 137054</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Rheumatologie de l'est du Quebec /ID# 135410</name>
      <address>
        <city>Rimouski</city>
        <zip>G5L 8W1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Latha Naik Medical Professional Corporation /ID# 135813</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research /ID# 135411</name>
      <address>
        <city>St. John's</city>
        <zip>A1B 3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Clare's Mercy Hospital /ID# 136737</name>
      <address>
        <city>St. Johns</city>
        <zip>A1C 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Juris Lazovskis Incorporated /ID# 134510</name>
      <address>
        <city>Sydney</city>
        <zip>B1S 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Arthur Karasik, Toronto, CANADA /ID# 134191</name>
      <address>
        <city>Toronto</city>
        <zip>M9B 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dr. Samuel K Silverberg /ID# 136496</name>
      <address>
        <city>Toronto</city>
        <zip>M9V 4B8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Arthritis Research Center /ID# 147466</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Jason Kur, Vancouver, Canada /ID# 135371</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Milton F. Baker Inc. /ID# 135288</name>
      <address>
        <city>Victoria</city>
        <zip>V8P 5P6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic /ID# 134830</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
  </link>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 5, 2017</lastchanged_date>
  <firstreceived_date>February 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
